Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

1 Jun 2021 08:52

RNS Number : 3978A
4d Pharma PLC
01 June 2021
 

4D pharma plc

(the "Company" or "4D")

Total Voting Rights

Leeds, UK, June 1, 2021 - 4D pharma plc (AIM: DDDD; NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that following the recent exercise of 1,239 warrants to subscribe for ordinary shares, the Company's issued share capital will comprise of 180,300,967 Ordinary Shares. The total number of voting rights in the Company will be 180,300,967.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

 

 

Contact Information:

4D pharma

Investor Relations: ir@4dpharmaplc.com

 

N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000

Philip Davies / Iqra Amin / James Fischer (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson / Phil Walker

 

Stern Investor Relations, Inc. +1-212-362-1200

Julie Seidel Julie.seidel@sternir.com

 

Image Box Communications +44 (0)20 8943 4685

Neil Hunter / Michelle Boxall

neil@ibcomms.agency / michelle@ibcomms.agency

 

About 4D pharma

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programmes, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in patients hospitalised with COVID-19, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programmes include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRDKDBQOBKKFAK
Date   Source Headline
9th Nov 20201:00 pmRNSSITC data MRx0518 monotherapy and combination
5th Nov 202012:00 pmRNSVirtual KOL Event SITC Data
30th Oct 20204:57 pmRNSHolding(s) in Company
23rd Oct 20201:17 pmRNSHolding(s) in Company
22nd Oct 20207:00 amRNSProposed Merger & Intention to seek NASDAQ Listing
14th Oct 202010:09 amRNSHolding(s) in Company
14th Oct 20207:00 amRNSPresentations on MRx0518 at SITC 2020
12th Oct 20202:01 pmRNSHolding(s) in Company
7th Oct 20207:00 amRNSTopline Results for Blautix phase II trial
30th Sep 20207:00 amRNSInterim Results
23rd Sep 20207:00 amRNSDirectorate Change
14th Sep 20204:30 pmRNSBlock Listing Six Monthly Return
7th Sep 20205:26 pmRNSHolding(s) in Company
1st Sep 20204:58 pmRNS4D hosts virtual R&D event
26th Aug 20207:00 amRNSMRx0158 Keytruda Part A clinical benefit data
14th Aug 20204:49 pmRNSHolding(s) in Company
12th Aug 20207:00 amRNSHolding(s) in Company
28th Jul 202010:34 amRNSHolding(s) in Company
24th Jul 20204:58 pmRNSHolding(s) in Company
20th Jul 20205:09 pmRNSHolding(s) in Company
16th Jul 20206:15 pmRNSHolding(s) in Company
16th Jul 20204:43 pmRNSHolding(s) in Company
15th Jul 20204:16 pmRNSHolding(s) in Company
13th Jul 20205:57 pmRNSResult of Fundraising
13th Jul 202012:13 pmRNSPlacing and Subscription of £7.7m
6th Jul 20207:00 amRNSOncology Clinical Update
2nd Jul 20204:02 pmRNSHolding(s) in Company
2nd Jul 20207:00 amRNSCOVID-19 study open for enrolment
30th Jun 20201:05 pmRNSResult of AGM
25th Jun 20207:00 amRNSHolding(s) in Company
22nd Jun 202011:19 amRNSHolding(s) in Company
10th Jun 20205:25 pmRNSHolding(s) in Company
10th Jun 20205:17 pmRNSHolding(s) in Company
10th Jun 202011:21 amRNSHolding(s) in Company
5th Jun 20201:00 pmRNSAnnual Report and Notice of AGM
5th Jun 20207:41 amRNS4D hosts virtual R&D event
26th May 20207:00 amRNSFinal Results
21st May 20207:00 amRNSDirectorate Change
19th May 20206:20 pmRNSHolding(s) in Company
12th May 20206:06 pmRNSHolding(s) in Company
11th May 20207:00 amRNSCompletion of immuno-oncology study safety phase
24th Apr 202011:30 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSPhase II study in COVID-19
17th Apr 20207:00 amRNSAppointment of Non-Executive Chairperson
17th Apr 20207:00 amRNSInterim analysis of Blautix phase II study data
30th Mar 202012:08 pmRNSSecond Price Monitoring Extn
30th Mar 202012:03 pmRNSPrice Monitoring Extension
19th Mar 20204:36 pmRNSPrice Monitoring Extension
19th Mar 20209:47 amRNSHolding(s) in Company
18th Mar 20204:44 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.